3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
5
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
Desmoid Tumors
1
Craniopharyngioma
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Anal Cancer Metastatic
1
Adenomatous Polyposis Coli
1
Interventions
Oxaliplatin
11
Fluorouracil
10
Capecitabine
9
Leucovorin
7
Radiotherapy
6
Nivolumab
6
Cetuximab
5
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Radiation
3
Bevacizumab
3
sintilimab
2
pembrolizumab
2
fludarabine
2
encorafenib
2
dostarlimab
2
aldesleukin
2
Trastuzumab
2
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Sigmoidoscopy
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Magnetic Resonance Imaging
2
Irinotecan
2
Gemcitabine
2
Folfox protocol
2
Endoscopy
2
Electrocardiography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
trifluridine tipiracil drug combination
×
30 days
×
Clear all
NCT06607458
2026-06-01
DEL-LIVER
Delcath Systems Inc.
Phase 2
Recruiting
90 enrolled